Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023)
Akari Therapeutics' (AKTX) quarterly Long-Term Deferred Tax came in at $42.2 million in Q4 2023, up 22.03% year-on-year from $34.6 million in Q4 2022, and up 22.03% quarter-over-quarter from $34.6 million in Q4 2022.
Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Akari Therapeutics has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $42.2 million for Q4 2023.
- Long-Term Deferred Tax for Q4 2023 came in at $42.2 million, up 22.03% year-over-year; the trailing twelve-month figure through Dec 2023 was $42.2 million (up 22.03% YoY), and the FY2023 annual result was $42.2 million, up 22.03% from the prior year.
- Long-Term Deferred Tax came in at $42.2 million for Q4 2023 at Akari Therapeutics, up from $34.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $42.2 million in Q4 2023 to a low of $34.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 42.24 Mn |
| Dec 31, 2022 | 34.62 Mn |